The PCOR-Vic Steering Committee governs all activities of PCOR-Vic, from day-to-day activities through to research projects.
Members of the steering committee
Professor Jeremy Millar (Chair)
Prof Jeremy Millar was the immediate past director of the southern Melbourne integrated cancer service (SMICS) and is currently director of radiation oncology at Alfred health in Melbourne. In addition to a busy clinical practice looking after patients there, he oversees both an academic radiation centre in metropolitan Melbourne, as well as Alfred Health's satellite regional centre in Gippsland. He leads the radiation oncology genito-urinary cancer group at Alfred health and, as part of this, developed and leads a large prostate brachytherapy program, as well as an external beam radiotherapy service. He is an adjunct associate professor at Monash university and his research and academic interests are mainly in prostate cancer. Jeremy has worked in leadership roles in a number of other capacities relating to prostate cancer care, such as the chairman of the Australasian brachytherapy group, chair of the genito-urological cancer committee of Victorian co-operative oncology group , and from 2011 the chair of the VCOG executive committee.
Professor Damien Bolton
Professor Bolton is director of urology at Austin Health and Professor of surgery, university of Melbourne. He is the current chair of the Victorian urologic oncology group of the cancer council. He has fifteen years post fellowship of the Australasian college of surgeons experience and is a member of multiple national and international learned societies, collaborative research groups, state and national committees, and national and international advisory boards. He is an elected member of the federal executive urological society of Australasia. Professor Bolton has a busy academic urologic practice, with particular interest in urologic oncology. He has a leadership role in urologic cancer research, research training of urologic registrars, and national and regional reference service for minimally invasive treatment of urological cancers. He has a key role in supervision of clinical research and in education and training in Austin Health cancer services.
Associate Professor Ian Davis
A/Prof Ian Davis is a medical oncologist working at Austin Health and the Ludwig institute for cancer research (LICR) in Melbourne, Australia, where he is head of the uro-oncology laboratory. He holds a Victorian cancer agency clinical researcher fellowship and is an NHMRC honorary practitioner fellow. His primary clinical interests are in urologic cancer and in melanoma, and his primary research interests are in cancer immunology and the biology of urologic cancers. A/Prof Davis is a member of the cancer council Victoria urology and skin committees and the standing subcommittee on research. He established and chairs the Cosa Urologic Oncology Group and the Australian and New Zealand urogenital and prostate cancer trials group ltd (ANZUP).
Associate Professor Sue Evans
A/Prof Evans is a leading Investigator on a research program within the School of Public Health and Preventive Medicine, Monash University focusing on developing clinical registry science. She is a senior research fellow within the Centre of Research Excellence in Patient Safety and a National Health and Medical Research Council (NHMRC) Postdoctoral Public Health Fellow. A/Prof Evans is Vice President of the Victorian Healthcare Quality Association and Editor of the Australian Patient Safety Bulletin. She is Coordinator and of the Master of Health Services Management Principles of Quality Improvement in Healthcare Unit and a senior lecturer within Monash University. A/Prof Evans completed a PhD (Department of Medicine, University of Adelaide) investigating barriers to reporting of error by medical and nursing staff. She instituted a number of strategies to improve reporting, including a 24 hour call centre, which was the first of its kind in Australia. A/Prof Evans is the database custodian of the prostate cancer registry.
Professor Albert Frauman
Professor Frauman is the Chair of Clinical Pharmacology & Therapeutics at the University of Melbourne. His major research activities involve drug discovery based on the use of biomarkers for prostate cancer metastasis as therapeutic and diagnostic targets. He is also Medical Director of the Austin Centre for Clinical Studies, a 16 bed phase I clinical trials unit. This integrated activity in drug discovery and development will allow for more efficient use of screening and testing of potential lead compounds for treatment of prostate cancer. In addition Professor Frauman has significant undergraduate and postgraduate teaching and training activities and is involved in quality use of medicines activities at hospital and national levels.
Associate Professor Mark Frydenberg
Associate Professor Mark Frydenberg graduated from the University of Melbourne, School of Medicine in 1982 with a MBBS (Hons) and was awarded FRACS in Urology in 1990. He then completed a formal urologic oncology fellowship specialising in prostate cancer management at the Mayo Clinic, USA. He works as a Urologist and Uro-oncologist within the multidisciplinary urology group Australian Urology Associates, as well as at Monash Medical Centre. He is currently the chairman of the Department of Urology at Monash Medical Centre and obtained a clinical associate professorship in the Monash University Departments of Surgery in 1997, and is Clinical Director of the Centre of Urological Research, Monash Institute of Medical Research. Associate Professor Mark Frydenberg is also chairman of the Urological Oncology Special Advisory Group of the Urological Society of Australia and New Zealand. He is a board member of Andrology Australia, and the uro-oncology representative on the Education Sub-committee of the Prostate Cancer Foundation of Australia. He is an editorial board member of the BJU International as well as the Brazilian Journal of Urology, and reviews for these journals as well as Urology, Journal of Urology, Urologic Oncology, Medical Journal of Australia and ANZ Journal of Surgery.
Professor John McNeil
Professor McNeil is head of the Monash University School of Public Health and Preventive Medicine, based at the Alfred hospital campus. After training as a physician he completed his PhD in clinical pharmacology and undertook post-doctoral training in epidemiology at the University of London’s School of Hygiene and Tropical medicine. His research interests have subsequently been focused on the application of epidemiological methods to problems in clinical medicine public health. A major part of this work has been on the development of clinical quality registries and their application to monitoring the safety and quality of medical care. His department is now a leading centre for clinical registries covering trauma, cardiovascular disease, cancer, rare diseases and high risk drugs and devices. The Registry Science Unit established within the School has become a leader in developing registry policy in areas covering governance, data management, ethics, financing and approaches to benchmarking. His school is regularly involved in sensitive an urgent public health investigations for government and industry. In 2010 he was awarded membership of the Order of Australia in recognition of his services to public health.
Associate Professor Declan Murphy
Declan Murphy moved to Melbourne, Australia in January 2010 to take up appointments as consultant urological surgeon at the Peter MacCallum Cancer Centre and the Royal Melbourne Hospital, and Director of Outcomes Research and Risk Stratification at the Australian Prostate Cancer Research Centre at Epworth Richmond. He had previously been consultant urological surgeon at Guys & St Thomas’ NHS Foundation Trust in London. His main interests are laparoscopic and robotic-assisted cancer surgery and he is Director of Robotic Surgery at Peter Mac. He has published extensively in the field of minimally-invasive urology and is on the editorial board of the Journal of Robotic Surgery and is a reviewer for European Urology, The Journal of Urology, the BJU International and the Journal of Sexual Medicine. Declan is honorary clinical Associate Professor at the University of Melbourne and co-director of the Fellowship programme at Royal Melbourne and the Peter MacCallum Cancer Centre.
Mr Max Shub
Max Shub is a survivor of Advanced Prostate Cancer. Following his cancer diagnosis, he joined Prostate Heidelberg in 2005. Since then, he has had a number of roles in the support group network at state and national levels As a cancer survivor he is passionate about supporting other people who are making the cancer journey, ensuring that their special needs are met, and that they receive the optimum treatment for their particular condition.
Dr Lachlan Dodds
Lachlan Dodds has been practising urology in Ballarat for almost 20 years. He has a broad experience in treating urological cancers with particular reference to prostate, kidney and bladder cancer and has skills in laparoscopy. He has a sub-specialty interest in paediatric urology and brachytherapy. Lachlan has been Chair of the Medical Advisory Committee at St John of God Hospital since 2010, is Head of the Urology Unit at Ballarat Health Services and has held leadership roles in the Urological Society for more than five years.
Dr Paul Kearns
Paul graduated from the University of Melbourne in 1994 with a bachelor of medicine and bachelor of surgery going on to completed urology training in South Australia and Victoria passing his fellowship exam in 2004.
Paul completed a further year of training in pelvic oncology in 2005 in Nottingham, UK, commencing practice in Geelong in 2006.
His main areas of interest are minimally invasive surgery to treat urological cancers, in particular robotic and laparoscopic surgery of the prostate and kidneys. He also has extensive experience in managing urinary stone disease and benign prostatic conditions, including greenlight laser.
Colin O’Brien is a former prostate cancer patient from 2005 who has held numerous roles as a consumer advocate and advisor with various cancer organisation including ANZUP, the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. He has 40 years-experience as a small business advisor and has a strong interest in benchmarking, particularly on the treatment and care of prostate cancer patients.
He has a B.A. (Econ), 1975, from Simon Fraser University in Canada and Grad. Dip. (Ed. Admin), Melbourne University, 1997.
Professor Tony Costello
Tony Costello is one of the leading prostate specialists in Australia.
Tony Costello is Professorial Fellow & Head Department of Urology, The Royal Melbourne Hospital, affiliated with Department of Surgery, University of Melbourne.
His private practice is conducted through Epworth Hospital Richmond campus and is primarily concerned with treatment of prostate cancer including robotic prostate surgery.
Tony pioneered robotic surgery in Australia. He now is into his seventh year of experience and at the Richmond campus, Epworth Hospital there have now been over 1,000 cases of robotic radical prostatectomy performed.
Prof Costello is an invited faculty member of the American Urological Association where annually he teaches aspects of robotic surgery to an international audience. He is also on the Editorial Board of the US publication Journal of Robotic Surgery, the British Journal of Urology and the Journal of Endourology.
Tony is the only Australian member of the American Association of Genitourinary Surgeons. The AAGUS is an Association of leading academic urologists from the United States, Canada and around the world dedicated to the study of diseases of the genitourinary system. Active membership is limited to 75 of the world’s most distinguished academic urological specialists.
Helen Farrugia has more than 25 years’ work experience in public health. This experience includes working on hospital based quality assurance programs, clinical trials, record linkage, screening register, family cancer register and population based cancer registry data capture and reporting. Helen’s role at the Cancer Council expanded to her current role as Director of the Victorian Cancer Registry since August 2011.
Helen’s vast experience includes representing CCV in the development and implementation of the Victorian Family Cancer Genetics program, responsibility for record linkage studies, overall management of the population based VCR and its associated external research programs as well as the Victorian Cancer Registry re-engineering project. Helen also sits on the Executive Board of the International Association of Cancer Registries (IACR) as the Oceania representative.